On December 26th, Mega Robotics and Hzymes Biotechnology Co., Ltd. (hereinafter referred to as “Hzymes “) officially announced the establishment of a strategic cooperation. The two parties will focus on the automation innovation demands in multiple fields such as molecular breeding, biopharmaceuticals, and synthetic biology. By combining Hzymes’ advanced biotechnology with Mega’s profound engineering expertise in AI and automation, they aim to provide global customers with more advanced and comprehensive integrated solutions, contributing to human health and well-being with technological wisdom and strength.

Hzymes, as a high-tech enterprise specializing in the research and development, production, application, and technical services of in vitro diagnostics and biopharmaceutical core raw materials, has been based on solid bioenzyme technology and related biological reagent research and production since its establishment in 2015. Relying on its core technology, it possesses technical platforms such as enzyme gene mining and performance characterization, enzyme molecular optimization and modification, enzyme gene high-throughput screening, organic synthesis, synthetic biology, and antigen-antibody research and preparation. It has become a leading enterprise in the core upstream raw material industry of biopharmaceuticals and in vitro diagnostics.

Mega Robotics, as a provider of advanced productivity tools, has created a series of high-precision, high-efficiency automated equipment and digital software platforms with its profound technical accumulation and continuous innovation capabilities. It is committed to building a new generation of laboratories that combine automation and artificial intelligence under the AI for Science paradigm. With Mega’s software and hardware technology capabilities, application development support, and cost-effective consumables, customers’ smart laboratories can truly be “built, used, and affordable.”

In this cooperation, the two parties will deeply collaborate in several key areas such as agricultural breeding, biopharmaceuticals, and synthetic biology. In the direction of agricultural breeding, the two parties will jointly launch a complete solution of automated equipment + reagent combinations, providing an “affordable” solution for breeding customers and accelerating the high-quality development of the agricultural breeding industry. In the biopharmaceutical QC segment, the two parties will provide automated equipment compatible with a variety of professional QC quality control kits, achieving full-process automation of QC testing, and helping QC laboratory testing accuracy and compliance reach new heights. At the same time, relying on the advanced facilities and technical platforms of the Kunpeng Laboratory of Mega, the two parties will launch a series of automated platforms and services in the field of synthetic biology, building a comprehensive solution for synthetic biology. In addition, the two parties also discussed more cooperation fields and directions in the meeting, and it is expected that they will further jointly expand into other fields such as animal husbandry and molecular diagnostics in the future. The partnership between Mega Robotics and Hanhai New Enzymes is not only a complementary and resource-sharing in the field of biotechnology but also injects strong momentum into the high-quality and sustainable development of the global agricultural breeding, biopharmaceutical, and synthetic biology industries. By integrating their core competencies in equipment, technology research and development, and application services, the two parties will set a new industry benchmark and promote the life science industry towards a new stage of intelligence and efficiency.

At present, the pace of innovation in the biopharmaceutical and life science fields is accelerating, and the rise of synthetic biology has brought new vitality to the next generation of biotechnology. Hzymes relies on the underlying technology of protein engineering, serving multiple fields such as biopharmaceuticals, in vitro diagnostics, and basic scientific research, and has an urgent demand for automated equipment. Mega Robotics has a clear advantage in intelligent automation. The two parties have a high degree of strategic synergy and complementarity, and their future development plans are highly consistent. I believe that by integrating the power of bioenzyme technology and intelligent automation, we can build cutting-edge biotech solutions and help the industry’s intelligent transformation reach new heights.

Hzymes’ outstanding achievements in the field of bioenzyme technology and biological reagent research and production are an important force in promoting the progress of biotechnology. Mega focuses on using advanced productivity tools such as AI and automation to empower digital innovation, making the world healthier and better. The in-depth advancement of this strategic cooperation is undoubtedly a key strategic move to promote the life science industry towards a new realm of intelligence and efficiency. I look forward to the strong synergistic effect of the two parties in the future, injecting a continuous stream of vitality into the vigorous development of the global life science field, and helping to open up more possibilities for innovation and breakthroughs.